Novo Nordisk is a Danish pharmaceutical company specialising in metabolic diseases. Its GLP-1 receptor agonist drugs — marketed as Ozempic and Wegovy — have made it the most valuable listed company in Europe.
Figures based on most recently reported fiscal year and trailing twelve months. For reference only.
Market Cap
$598B
Annual Revenue
$34B
Net Income
$11.5B
P/E Ratio
52.1
Dividend Yield
1.1%
52-Week High
$148.20
52-Week Low
$72.40
Avg. Daily Volume
8.4M
A century ago, Novo Nordisk's predecessors were racing to produce insulin for the newly diagnosed diabetic patients of Scandinavia. Today, the company finds itself at the centre of what may be the most significant pharmaceutical development of the 21st century: a class of drugs that can treat not just diabetes and obesity, but potentially a wide range of metabolic, cardiovascular, and neurological conditions. The active ingredient, semaglutide, works by mimicking a hormone that regulates appetite and blood sugar. Its effectiveness for weight loss — clinical trials showed average reductions of 15-20% of body weight — triggered a demand surge that the company has struggled to meet. Novo Nordisk has committed billions to expanding manufacturing capacity, acquiring fill-and-finish facilities across Europe and North America. The competitive landscape is intensifying: Eli Lilly's tirzepatide (Mounjaro/Zepbound) has emerged as a credible rival, and a wave of oral GLP-1 candidates from multiple companies is moving through clinical trials. Novo Nordisk's challenge is to maintain its first-mover advantage while the market it created rapidly expands.
Founded
April 1, 1976
Employees
~164,000 full-time
Headquarters
Cupertino, California
Key Segments
iPhone, Mac, iPad, Wearables, Services
Founded
April 5, 1993
Employees
~29,600 full-time
Headquarters
Santa Clara, California
Core Platform
CUDA / Blackwell GPU Architecture
Founded
July 1, 2003
Employees
~140,000 full-time
Headquarters
Austin, Texas
Gigafactories
Fremont, Austin, Berlin, Shanghai
Founded
1923 (merged entity)
Employees
~64,000 full-time
Headquarters
Bagsværd, Denmark
Key Compounds
Semaglutide (Ozempic, Wegovy)
Founded
May 29, 1933
Employees
~70,000 full-time
Headquarters
Dhahran, Saudi Arabia
Daily Production
~9.5 million barrels/day
Founded
1799 (legacy entity)
Employees
~316,000 full-time
Headquarters
New York, New York
Total Assets
~$3.9 trillion
Lars Fruergaard Jørgensen
President & Chief Executive Officer
Since January 2017
Lars Fruergaard Jørgensen joined Novo Nordisk in 1991 and spent his early career in finance and IT before moving into general management. He became CEO in 2017, inheriting a company that was already a leader in diabetes care but had not yet seen the full commercial potential of its GLP-1 pipeline. His tenure has been defined by the global rollout of Ozempic and Wegovy, a dramatic expansion of manufacturing capacity, and the challenge of managing a company whose growth has outpaced its own ability to supply product.
52-Week Range
A rare alignment of monetary policy signals from the Fed, ECB, and Bank of Japan is reshaping capital flows and forcing institutional investors to rethink decade-long positioning strategies.
Gulf state sovereign wealth funds are quietly executing the largest portfolio rebalancing in a generation, moving out of US Treasuries and into infrastructure, private equity, and emerging market equities.
Structural shifts in labor markets, the AI productivity boom, and unprecedented fiscal deficits have fundamentally altered the business cycle.
As NVIDIA's dominance faces its first credible challenge, a new front in the semiconductor race is opening — one that could reshape the entire technology industry.
After three years of record prices, the ultra-prime property market in New York, London, and Dubai is showing the first signs of a meaningful correction.
With Tesla's market share under pressure, legacy automakers burning through capital, and Chinese brands flooding Western markets, the electric vehicle industry faces its most brutal consolidation yet.
GLP-1 agonists have already transformed Novo Nordisk and Eli Lilly into pharmaceutical giants. The next wave of obesity treatments could be even more disruptive.
The IEA says the world needs to triple clean energy investment by 2030. The money is not materialising fast enough — and the consequences could be severe.
After a brutal 2023 correction, venture capital is flooding back into AI startups at a pace that is raising uncomfortable questions about valuation discipline.
Founded by three former DeepMind and Meta researchers, Mistral AI has built a €6 billion business in under two years by betting that open-weight models and European sovereignty would matter more than Silicon Valley scale.
While rivals chased enterprise contracts and IPO valuations, SumUp spent a decade building payment infrastructure for market traders, hairdressers, and food trucks. Now it is one of Europe's most valuable private fintech companies.
Munich-based Personio has built the leading HR platform for small and mid-sized businesses across Europe, reaching a valuation of €8 billion by solving a problem that American software giants consistently ignored.
The Swedish gigafactory startup raised over $15 billion, secured contracts with BMW and Volkswagen, and was hailed as Europe's answer to Tesla's battery dominance. Then production targets collapsed, customers walked, and the company filed for bankruptcy protection. The lessons are uncomfortable for the entire continent.
Founded in Szczecin in 2013 by Tytus Gołas, Tidio grew from a simple live chat widget into a customer service platform used by over 300,000 businesses worldwide — without raising significant external capital for most of its existence. It is a case study in what European bootstrapping can achieve.
Founded in 2016 by Barney Hussey-Yeo, Cleo built an AI-powered money coach that speaks to young adults in plain language. With modest early funding and a product that feels more like a friend than a bank, it quietly became one of the UK fintech scene's most interesting small bets.
What began in 2012 as a simple marketplace connecting small businesses with local accountants has evolved, slowly and deliberately, into a broader financial services platform for European SMEs. Ageras is not a unicorn. It is something rarer: a profitable small company with a clear thesis.
Getting a driving licence in France has historically been expensive, slow, and opaque. Ornikar, founded in Paris in 2014, set out to fix all three problems at once — and in doing so revealed how much regulatory capture had inflated the cost of a basic life skill.
Founded in Dublin in 2019 by Aidan Corbett and Jack Pierse, Wayflyer built a revenue-based financing product for online merchants who needed working capital but could not get it from traditional lenders. The timing — just before the pandemic ecommerce boom — turned out to be fortunate.
Spun out of ETH Zurich in 2019 by a team of food scientists, Planted has built a plant-based meat product using a high-moisture extrusion process that produces a texture closer to whole-muscle meat than most competitors. It is a small company with a serious scientific thesis.